Trading in Nightingale Health’s B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US

Nightingale Health Plc, stock exchange release, 21 March 2025 at 1:00 p.m. (EET)   Nightingale Health Plc (“Nightingale Health” or the “Company”) announced on 17 March 2025 that the Company had submitted a request to OTC Markets Group Inc. (“OTC Markets”) for the admission of the Series B shares (the “Shares”) to trading on the OTCQX International market so that the first trading day would be on 19 March 2025, at the earliest, and 24 March 2025, at the latest. The Company confirms that trading in the B Shares and ADRs commences today, 21 March 2025, on the OTCQX International market.

Nightingale Health Plc’s listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025

Nightingale Health Plc Stock exchange release 18 March 2025 at 11:30 a.m. EET   Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) has today approved the listing application of Nightingale Health Plc (“Nightingale Health” or the “Company”) to admit the Company’s Series B shares (the “Shares”) to trading on the Main Market of Nasdaq Helsinki. Trading in the Shares commences on the Main Market of Nasdaq Helsinki on 19 March 2025, with the trading code HEALTH. The total number of Shares to be admitted to trading is 40,302,841 Shares.   Nightingale Health will transfer to the Main Market

The Finnish Financial Supervisory Authority has approved Nightingale Health Plc’s Finnish prospectus

Nightingale Health Plc Stock exchange release 17 March 2025 at 4:15 p.m. EET   The Finnish Financial Supervisory Authority today approved Nightingale Health Plc’s (“Nightingale Health” or the “Company”) Finnish-language prospectus (the “Finnish Prospectus”) in connection with the Company’s transfer from the Nasdaq First North Growth Market Finland marketplace to the Main Market of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”).   The Finnish Prospectus will be available on or about 17 March 2025 on Nightingale Health’s website at https://ir.nightingalehealth.com/fi/

Nightingale Health establishes ADR program in the US – trading in Company’s B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US

Nightingale Health Plc Stock exchange release 17 March 2025 at 1:55 p.m. (EET)   Nightingale Health Plc (“Nightingale Health” or the “Company”) announced on 27 November 2024 that it was investigating the possibility of starting trading in the Company’s Series B shares (the “Shares”) on the OTCQX International market managed by OTC Markets Group Inc. (“OTC Markets”) in the United States, with the aim of improving the liquidity of the Share and of achieving a broader international shareholder base. The Company has today submitted a request to OTC Markets for the admission of the

Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki

Nightingale Health PlcStock exchange release12 March 2025 at 2:30 p.m. (EET) Nightingale Health Plc (“Nightingale Health” or the “Company”) has today submitted a listing application with Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) to admit the Company’s series B shares (the “Shares”) on trading on the Main Market of Nasdaq Helsinki (the “Listing”). The Listing is conditional upon Nasdaq Helsinki approving the Company’s listing application and the Finnish Financial Supervisory Authority approving the prospectus prepared in connection with the Listing. Trading in the Shares is expected

Nightingale Health’s half-year report: International expansion continues in Southeast Asia and the United States

Nightingale Health Group’s Half-year report 1 July 2024 – 31 December 2024 (unaudited)   Nightingale Health’s half-year report: International expansion continues in Southeast Asia and the United StatesCompany release, 6 March 2025 at 9:00 a.m. (EET)   This release is a summary of Nightingale Health Plc's Half-year report from period 1 July 2024 – 31 December 2024. The full Half-year report is attached to this release.   Numbers presented in brackets refer to corresponding year-on-year period unless otherwise stated.July-December 2024 key financials (IFRS)   -

Nightingale Health to publish half-year report for July – December 2024 on 6 March 2025

Nightingale Health PlcPress release28 February 2025 at 12:35 p.m. (EET) Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, will publish its half-year report for July – December 2024 on Thursday 6 March 2025 at around 9 a.m. EET. The materials will be made available soon after publication at http://ir.nightingalehealth.com.     Nightingale Health will arrange a live webcast for investors and media in English on 6 March 2025 at 2 p.m. EET. You can watch the webcast online at:nightingalehealth.events.inderes.com/2024-2025-h1-

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks

Nightingale Health PlcPress release27 February 2025 at 2:15 p.m. (EET) Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health announces the development of an innovative LLM based tool to make its results report more interactive and actionable. The tool, powered by large language models (LLMs), leverages the multi-disease risk detection and blood value data from Nightingale Health’s proprietary blood test and combines these with publicly available information about which lifestyle interventions most effectively reduce the risk of

Nightingale Health announces its updated regulatory plan in the United States

Nightingale Health PlcPress release7 February 2025 at 2:15 p.m. (EET) Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health announces its regulatory plan for the U.S. market. Nightingale Health announced last year that it will establish a laboratory in the U.S., and has now selected the State of New York as the location for the laboratory. This location provides significant benefits for the regulatory pathway for Nightingale Health’s services as FDA premarket review is not required (as described below). FDA’s latest rule on

Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Nightingale Health Plc Press release 27 January 2025 at 9:00 a.m. (EET)   Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, and Enigma Genomics (“Enigma”) have signed a pilot agreement and a letter of intent to provide the Nightingale Remote Health Check to Enigma’s customers in the Kingdom of Saudi Arabia and the MENA region.   Enigma , an innovative AI-powered genomics platform, is aiming to transform healthcare with advanced genetic analysis for diagnostic and research purposes.

Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States

Nightingale Health Plc Press release 23 January 2025 at 11:00 a.m. (EET)   Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, today announces performance metrics of the latest generation of its disease risk assessments that will be rolled out in Singapore and United States as a part of its Health Check product line. The latest generation of the disease risk assessments have taken advantage of Nightingale Health’s growing and diverse global data resources and the latest machine learning techniques to provide the world

Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Nightingale Health PlcCompany release23 December 2024 at 2:00 p.m. (EET)  The Board of Directors of Nightingale Health Plc (“Nightingale Health”) has in its meeting on 21 November 2024 approved request of shareholders to convert 6,020 EMP shares to Series B shares in accordance with Article 5 in the Articles of Association.   As a result of conversion of shares, the number of the Nightingale Health’s Series A shares is 19,526,438, Series B shares is 40,302,841 and EMP shares is 1,098,800. The conversion does not affect the total amount of shares which is 60,928,079. The number

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health Plc Managers’ Transactions 20 December 2024 at 5:35 p.m. (EET)     Person subject to the notification requirement Name: Cor Group Oy Position: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer Name: Olli Karhi Position: Member of the Board Issuer: Nightingale Health Oyj LEI: 743700WUIPC24LVMLO66 Notification type: INITIAL NOTIFICATION Reference number: 88799/5/4   ____________________________________________ Transaction date: 2024-12-18 Outside a trading venue

Nightingale Health Plc appoints Lago Kapital as liquidity provider

Nightingale Health PlcCompany release18 December 2024 at 9:35 p.m. (EET) Nightingale Health Plc (“Nightingale Health”) has entered into a Liquidity Providing (LP) agreement with Lago Kapital Ltd (“Lago”) within the framework of Nasdaq First North Growth Market rules for liquidity provision. According to the agreement, Lago will quote bids and offers for Nightingale Health's share in such a way that the spread of the bid and offer prices is a maximum of 3% calculated from the bid price. The quotes on bid and offer must be at least EUR 3,000 worth of shares. Lago shall quote bids

Nightingale Health Plc: Subscription of Series B shares with option rights

Nightingale Health PlcCompany release13 December 2024 at 3:50 p.m. (EET) Based on Nightingale Health Plc’s option program 2023-ML, 3,600 new Series B shares have been subscribed. As a result of the share subscription approved by Nightingale Health’s Board of Directors on 21 November 2024, the number of Series B shares in the company will increase from 40,293,221 to 40,296,821 shares. The subscription price of the subscriptions made with the option rights, EUR 9,000, will be entered in the company’s reserve for invested unrestricted equity.   The shares subscribed with option

Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Nightingale Health Plc Press release 4 December 2024 at 10:00 a.m. (EET)   Nightingale Health Plc’s (“Nightingale Health”) peer-reviewed study  has been published in Nature Communications, showcasing the accuracy and performance of Nightingale Health’s blood biomarker-based risk prediction models. The world’s largest population study in the field includes data from more than 700,000 participants in three national biobanks from Finland, Estonia and the United Kingdom. The population study findings show that Nightingale Health’

Nightingale Health announces opening of its Singapore laboratory

Nightingale Health PlcPress release29 November 2024 at 11:30 a.m. (EET) Nightingale Health, a pioneer in disease risk detection and preventative health announces the opening of its Singapore laboratory: the opening ceremony that will be held on Monday 2nd December 2024 marks an important milestone in Nightingale Health’s global expansion. Located in the hub of Southeast Asia, the laboratory is now ready to serve healthcare and medical research customers in the region. Nightingale Health announced earlier this month that it has the regulatory readiness to start providing its blood

Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S.

Nightingale Health PlcCompany releaseInside information27 November 2024 at 2:20 p.m. (EET) The Board of Directors of Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, has decided to investigate the possible transfer of the company’s publicly traded series B shares (the “Shares”) from Nasdaq First North Growth Market Finland to the main market of Nasdaq Helsinki Ltd (the “Main Market”) and the possible cross-trading of the Shares on the OTCQX market, managed by the OTC Markets Group Inc. (“OTC Markets”) in the United States.

Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore

Nightingale Health Plc Press release 14 November 2024 at 9:15 a.m. (EET)   Nightingale Health Plc’s Singaporean subsidiary Nightingale Health Asia Pte. Ltd. (“Nightingale Health”) has been granted ISO 13485:2016 certification. ISO 13485 is the international quality management system standard for the design, production and distribution of medical devices. ISO 13485 is a requirement for medical device distribution in Singapore, and together with the earlier announced Health Sciences Authority approvals, this certification makes Nightingale Health ready to launch its blood testing

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Nightingale Health PlcCompany release8 November 2024 at 5:00 p.m. (EET) The Annual General Meeting of Nightingale Health Plc was held on 8 November 2024. The meeting was held as a fully virtual remote meeting in accordance with Chapter 5, Section 16, Subsection 3 of the Finnish Companies Act. The General Meeting adopted the Financial Statements and the Consolidated Financial Statements, discharged the members of the Board of Directors and the CEO from liability and approved in an advisory vote the Remuneration Report of the governing bodies for the financial period of 1 July 2023–30

Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer

Nightingale Health Plc Press release 6 November 2024 at 09:45 a.m. (EET)   Nightingale Health, a pioneer in disease risk detection and preventative health has appointed internationally recognised expert in medicine Dr. Charles Alessi as Chief Medical Officer of Nightingale Health UK.   Dr. Charles Alessi is a physician with more than 35 years of experience in all aspects of policy and clinical practice in the United Kingdom, Northern Ireland and globally. Alessi’s experience includes key positions in some of the world leading organisations in the industry, such as acting

Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use of Nightingale’s Health Check in the US

Nightingale Health Plc Press release 30 October 2024 at 09:35 a.m. (EET)   Nightingale Health Plc’s US subsidiary Nightingale Health United States Inc. (“Nightingale Health”) and Boston Heart Diagnostics Corporation (“Boston Heart”) have successfully completed the pilot announced in June, and have signed an agreement to start providing Nightingale’s blood test based Health Check to Boston Heart’s customers.   Boston Heart is an innovative heart health focused company that provides a leading, advanced diagnostics platform to help identify and reduce the risk of

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health PlcCompany release10 October 2024 at 1:00 p.m. (EEST) The Annual General Meeting of Nightingale Health Plc will be held on Friday, 8 November 2024, beginning at 3:00 p.m. (EET). The Meeting will be held as a remote meeting in accordance with Chapter 5, Section 16, Subsection 3 of the Finnish Companies Act, in which shareholders fully exercise their decision-making powers by the use of telecommunications and technical means during the Meeting in real time. The remote meeting does not have a physical meeting venue which shareholders or their proxy representatives

Nightingale Health’s Annual Report for financial year 2023–2024 has been published

Nightingale Health PlcCompany release10 October 2024 at 09:00 a.m. (EEST)  Nightingale Health Plc’s Annual Report for financial year 1 July 2023–30 June 2024 has been published. The publication includes the Board of Directors' Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report. The Annual Report, the Corporate Governance Statement, and the Remuneration Report are attached to this release and are also available on Nightingale Health’s website at https://ir.nightingalehealth.com/. For further